1/24
Comprehensive vocabulary study cards covering basic pharmacology concepts, pharmacokinetics (ADME), biotransformation, hepatobiliary and renal excretion, quantitative clearance and half-life kinetics, and fundamental pharmacodynamics.
Pharmacokinetics
The study of what the body does to a drug, tracking its movement through the body via absorption, distribution, metabolism, and excretion (ADME).
Pharmacodynamics
The study of what a drug does to the body, encompassing biochemical and physiological mechanisms, receptor binding, and dose-response relationships.
Therapeutic Index (TI)
A quantitative ratio reflecting drug safety, determined by comparing toxic or lethal dose to effective dose: TI=ED</em>50TD<em>50
Intravenous route of administration
The route that injects a compound directly into the vascular compartment, completely bypassing absorption to achieve 100% bioavailability.
pH-partition hypothesis
The principle stating that weak acids remain predominantly un-ionized and lipid-permeable in acidic media, whereas weak bases remain un-ionized in alkaline environments.
Small intestine
The principal anatomical site of oral drug absorption for both weak acids and weak bases, driven by extensive mucosal surface area and high blood flow.
First-pass metabolism
The presystemic hepatic clearance of an orally administered drug absorbed from the gastrointestinal tract into the portal vein before reaching systemic circulation.
Bioavailability (F)
The fraction or percentage of an administered drug dose that successfully enters systemic circulation in an unchanged chemical state.
Apparent volume of distribution (Vd)
A theoretical proportionality constant relating the total amount of drug present in the body to its concentration in plasma: V<em>d=C</em>pAmount of drug
Free drug fraction
The unbound portion of circulating drug capable of diffusing across biological membranes, interacting with receptors, and undergoing metabolic and renal clearance.
Phase I drug metabolism
Non-synthetic functionalization reactions—principally oxidation, reduction, and hydrolysis catalyzed by Cytochrome P450 enzymes—that introduce or unmask polar chemical groups.
Phase II drug metabolism
Synthetic conjugation reactions that link parent drugs or Phase I products to endogenous polar moieties (such as glucuronic acid or glutathione) to form excretable hydrophilic conjugates.
Enzyme induction
The enhanced expression and catalytic capacity of hepatic microsomal enzymes triggered by specific agents, leading to accelerated metabolism and reduced efficacy of co-administered drugs.
Enzyme inhibition
The reduction in catalytic activity of drug-metabolizing enzymes by a competing compound, leading to reduced clearance and potential toxicity of co-administered drugs.
Probenecid interaction with Penicillin
Competitive inhibition of organic anion transporters (OATs) in the proximal renal tubule, reducing renal tubular secretion and prolonging the antibiotic's half-life.
Urinary alkalinization
The therapeutic infusion of sodium bicarbonate to ionize weak acids in renal tubules, trapping them in urine to accelerate elimination during an overdose.
Enterohepatic circulation
The biliary excretion of glucuronide conjugates followed by bacterial β-glucuronidase hydrolysis in the bowel, which liberates free lipophilic drug for intestinal reabsorption.
Drug clearance (CL)
The theoretical volume of plasma completely cleared of a drug per unit of time across eliminating organs: CL=k<em>e×V</em>d
Elimination half-life (t1/2)
The duration required for plasma drug concentration to decrease by half during the post-absorptive elimination phase: t<em>1/2=CL0.693×V</em>d
First-order kinetics
A linear elimination pattern in which a constant fraction of drug is eliminated per unit of time, keeping clearance and half-life independent of drug concentration.
Zero-order kinetics
A nonlinear elimination pattern where a constant absolute amount of drug is cleared per unit of time because metabolizing enzymes or transport mechanisms are fully saturated.
Steady state (Css)
The dynamic equilibrium achieved during continuous or repeated dosing when drug administration rate equals elimination rate, typically requiring 4 to 5 half-lives.
Loading dose (LD)
A large initial dose calculated using volume of distribution (Vd) to achieve therapeutic plasma levels rapidly without waiting for steady state to accumulate over multiple half-lives.
Competitive antagonist
A ligand that reversibly binds the agonist's receptor site, shifting the concentration-response curve to the right without reducing maximal response (Emax).
Non-competitive antagonist
An agent that binds allosterically or irreversibly to a receptor, depressing the maximal achievable response (Emax) regardless of how much agonist is added.